Kyverna Therapeutics Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

130

Market Cap

526.61M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	-	-	-
Dec 31, 2024	-	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	7.03M	1.37M	24.20%
Dec 31, 2021	5.66M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Rigel Pharmaceuticals	294.28M
Sutro Biopharma	102.48M
Fulcrum Therapeutics	80.00M
Ocugen	4.41M
Altimmune	41.00K
Lyell Immunopharma	36.00K

Revenue Rankings

KYTX News

7 days ago - Kyverna Therapeutics Transcript: Status update - Transcripts
7 days ago - Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting - GlobeNewsWire
8 days ago - Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks - GlobeNewsWire
19 days ago - Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026 - GlobeNewsWire
4 weeks ago - Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
7 weeks ago - Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
7 weeks ago - Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - GlobeNewsWire
2 months ago - Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire

More News